Share This! Tweet This! Recommend Us! Print Page
Language

Current Cancer Trials

Find a Doctor
Find a Location

Participate in One of These Clinical Trials

Brain

RTOG 0834 

Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial.

Protocol Summary

Consent Form (Screening) - Password Protected

Consent Form (Main) - Password Protected

ALLIANCE A071102

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Protocol Summary

Consent Form (Screening) - Password Protected

Consent Form (Main) - Password Protected

ALLIANCE A221101

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma

Protocol Summary

Consent Form - Password Protected


Breast

EA1131

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Protocol Summary

Consent Form - Password Protected

NSABP B-55

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Protocol Summary

Consent Form (Pre Entry) - Password Protected

Consent Form (Treatment) - Password Protected

SCCA 6628

A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targetd Therapy with Bevacizumab and Erlotinib

Protocol Summary

ECOG 2108

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patents with Metastatic Breast Cancer

Protocol Summary

Consent Form - Password Protected

8093

Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Protocol Summary

SWOG 1007 (Quality of Life - Closed)

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

Protocol Summary

Consent Form (Step 1) - Password Protected

Consent Form (Step 2) - Password Protected

SWOG 1207

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy

Protocol Summary

Consent Form - Password Protected


ALLIANCE A011203

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

Protocol Summary

Consent Form - Password Protected

NSABP B-52

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or Without Estrogen Deprivation

Protocol Summary

Consent Form - Password Protected

Consent Form Addendum (for patients prior to 4-21-15) - Password Protected

NSABP B-51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Protocol Summary

Consent Form - Password Protected

Alliance A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Protocol Summary

Consent Form - Password Protected

SWOG 1202

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer

Protocol Summary

Consent Form - Password Protected

14-002

-Note: Arms A & B now closed-

Genomic markers in BREAST cancer:  sample acquisition for methods development and discovery

Gastrointestinal

CALGB 80702

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.

Protocol Summary

Consent Form - Password Protected

SWOG 0820

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Protocol Summary

Consent Form - Password Protected

RTOG 1010


A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Protocol Summary

Consent Form - Password Protected

CALGB 80802

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)

Protocol Summary

Consent Form - Password Protected

RTOG 0848

A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

Protocol Summary

Consent Form - Password Protected

ECOG 2211

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors

Protocol Summary

Consent Form - Password Protected

ALLIANCE N1048

A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Protocol Summary

Consent Form - Password Protected

Genitourinary

ALLIANCE A031201

Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Protocol Summary

Consent Form - Password Protected

CALGB 90203

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

Protocol Summary

Consent Form - Password Protected

CALGB 70807

The Men's Eating and Living (MEAL) Study: A Randomized Trial of diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance.

Protocol Summary

Consent Form - Password Protected

SWOG 1216

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

Protocol Summary

Consent Form - Password Protected

SWOG 0931

EVEREST:  Everolimus for Renal Cancer Ensuring Surgical Therapy, a Phase III Study 

Protocol Summary

Consent Form - Password Protected

ECOG 2810 

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Protocol Summary

Consent Form - Password Protected

Gynecologic

RTOG 0724

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy.

Protocol Summary

Consent Form - Password Protected

RTOG 1203

A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)

Protocol Summary

Consent Form - Password Protected

GOG 0286B

A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Protocol Summary

Consent Form - Password Protected

GOG 0277

A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma

Protocol Summary

Consent Form - Password Protected

GOG 0281

A Randomized Phase II/III Study to Assess The Efficacy of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Protocol Summary

Consent Form - Password Protected

E1Q11

EROS: Engendering Reproductive Health Within Oncologic Survivorship

Protocol Summary

Consent Form (Main) - Password Protected

Consent Form (Provider) - Password Protected

GOG 0225

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

Protocol Summary

Consent Form - Password Protected

NRG CC-002

Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers

Protocol Summary

Consent Form - Password Protected

Head & Neck

None at this time


Hematology

ECOG 1912

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Protocol Summary

Consent Form - Password Protected

REVEAL:  PRospective ObsErvational Study of Patients with Polycythemia VEra in US ClinicAL Practices

Protocol Summary

Lung

ALLIANCE A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Protocol Summary

Consent Form - Password Protected

ALLIANCE A081105

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Protocol Summary

Consent Form - Password Protected

D5160C00003

A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3)

Protocol Summary

ECOG 4512

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Protocol Summary

Consent Form - Password Protected

SCCA 7755 

A Phase II study of weekly Abraxane (nab-paclitaxel) for patients with advanced NSCLC with EGFR mutations following front-line therapy with EGFR tyrosine kinase inhibitors

Protocol Summary

SWOG 1400 (LUNG-MAP)

-Note:  Sub-Study E and Arm 2 of Sub-Study A closed-

Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

Protocol Summary

Consent Form (Pre-Screening) - Password Protected

Consent Form (Screening) - Password Protected

Consent Form (Arm A) - Password Protected

Consent Form (Arm B) - Password Protected

Consent Form (Arm C) - Password Protected

Consent Form (Arm D) - Password Protected

100070-004

A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-small Cell Lung Cancer That Has Progressed After a Platinum-containing Doublet

Protocol Summary


Lymphoma

None at this time

Melanoma

103A-301

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence

Protocol Summary

SWOG 1320

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

Protocol Summary

Consent Form - Password Protected

Multiple Myeloma

ECOG-ACRIN E3A06

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Protocol Summary

Other

FH 7159 (Limited Institutions)

Advanced PET/CT Imaging for Clinical Trials 

NCI 9846

-Note:  Open to MultiCare Health System and Virginia Mason Medical Center sites only-

Patient-derived Models Tissue Procurement Protocol for the National Cancer Institute (P9846)

Consent Form - Password Protected

NCI 9671

Exceptional Responders Pilot study:  Molecular profiling of tumors from cancer patients who are Exceptional Responders

Protocol Summary

Consent Form - Password Protected

CBGJ398XUS04

-Note:  Breast & Colorectal cohorts temporarily closed to enrollment

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations

Protocol Summary

URCC 13059 (GAP 70+)

A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer:  Reducing Chemotherapy Toxicity in Older Adults

Protocol Summary

Consent Form (Main) - Password Protected

Physician Information Sheet (if not available online) - Password Protected

URCC 13070 (COACH)

Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers

Protocol Summary

Consent Form (Main) - Password Protected

Consent Form (Caregiver) - Password Protected

Physician Information Sheet (if not available online) - Password Protected


For more information and/or copies of protocols:

Contact Michelle Maxin-Wells by phone at 253-403-7193, or by email: michelle.maxin-wells@multicare.org